NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship

ImpediMed Presents at Bioshares Biotech Summit 2016

BRISBANE, Australia and CARLSBAD, Calif., July 29, 2016 /PRNewswire/ — ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, announced that Managing Director and CEO, Richard Carreon, presented at the Bioshares Biotech Summit 2016 in Queenstown, New Zealand, on Friday, July 29, 2016.

The topic for the presentation was “Opportunities for Digital Health Solutions.” The presentation included details of ImpediMed’s current work on its next generation product, SOZO™, including a video describing the product.

SOZO™ is considered by ImpediMed to have the world’s most accurate technology for use in body composition, fluid status and hydration management, combined with the technology of remote patient monitoring. This next generation system features convenient and easy-to-use characteristics along with compatibility to interact with either the medical clinic or the user’s own device.

ImpediMed will update the market as SOZO™ receives appropriate regulatory clearances for the relevant indications.

A copy of the presentation is available on ImpediMed’s website at

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men.

For additional information, visit